- Home
- ABUS vs ACIC Comparison
ABUS vs ACIC Comparison
Compare ABUS & ACIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABUS
- ACIC
- Stock Information
- Founded
- ABUS 2005
- ACIC 1999
- Country
- ABUS United States
- ACIC United States
- Employees
- ABUS N/A
- ACIC N/A
- Industry
- ABUS Biotechnology: Pharmaceutical Preparations
- ACIC Property-Casualty Insurers
- Sector
- ABUS Health Care
- ACIC Finance
- Exchange
- ABUS Nasdaq
- ACIC Nasdaq
- Market Cap
- ABUS 711.2M
- ACIC 546.2M
- IPO Year
- ABUS N/A
- ACIC N/A
- Fundamental
- Price
- ABUS $4.28
- ACIC $11.97
- Analyst Decision
- ABUS Strong Buy
- ACIC Buy
- Analyst Count
- ABUS 2
- ACIC 1
- Target Price
- ABUS $5.00
- ACIC $16.00
- AVG Volume (30 Days)
- ABUS 988.6K
- ACIC 159.0K
- Earning Date
- ABUS 11-05-2025
- ACIC 11-05-2025
- Dividend Yield
- ABUS N/A
- ACIC 4.26%
- EPS Growth
- ABUS N/A
- ACIC 14.01
- EPS
- ABUS N/A
- ACIC 1.63
- Revenue
- ABUS $15,416,000.00
- ACIC $320,072,000.00
- Revenue This Year
- ABUS $138.02
- ACIC $4.91
- Revenue Next Year
- ABUS N/A
- ACIC $4.16
- P/E Ratio
- ABUS N/A
- ACIC $7.19
- Revenue Growth
- ABUS 53.23
- ACIC 33.90
- 52 Week Low
- ABUS $2.71
- ACIC $9.97
- 52 Week High
- ABUS $5.10
- ACIC $15.08
- Technical
- Relative Strength Index (RSI)
- ABUS 50.78
- ACIC 57.01
- Support Level
- ABUS $4.10
- ACIC $11.04
- Resistance Level
- ABUS $4.54
- ACIC $12.41
- Average True Range (ATR)
- ABUS 0.18
- ACIC 0.30
- MACD
- ABUS -0.06
- ACIC 0.04
- Stochastic Oscillator
- ABUS 32.15
- ACIC 57.82
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
About ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary.